ArticleCirculation research2019
Comparative Analysis of Circulating Noncoding RNAs Versus Protein Biomarkers in the Detection of Myocardial Injury.
Article in Circulation research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 3 syntheses or guidelines pooled it, 121 citations in OpenAlex.
- Bridging the Troponin Blind Window via the miAMI Standard: A Systematic Review and Meta-Analysis of the Circulating MicroRNA-208 Family.Medicina (Kaunas, Lithuania) · 2026Pooled it
- Systematic Review: Urine Biomarker Discovery for Inflammatory Bowel Disease Diagnosis.International journal of molecular sciences · 2023Pooled it
- MicroRNAs as Prognostic Markers in Acute Coronary Syndrome Patients-A Systematic Review.Cells · 2019Pooled it
- Platelets and inflammation-insights from platelet non-coding RNA content and release in the Bruneck study and the PACMAN-AMI trial.Cardiovascular research · 2025Trial
- Preparation of Optical-Based Sensors for the Determination of Cardiac Myosin-Binding Protein C.ACS omega · 2026Article
- MicroRNA mapping of bronchial aspirate for molecular phenotyping and prognostication in patients on mechanical ventilation.Molecular therapy. Nucleic acids · 2025Article
- The European BestAgeing Study on microRNA candidates reveals distinct signatures with diagnostic and prognostic potential in cardiovascular disease.BMC medicine · 2025Article
- Prognostic value of combining cardiac myosin-binding protein C and N-terminal pro-B-type natriuretic peptide in patients without acute coronary syndrome treated at medical cardiac intensive care units.Heart and vessels · 2025Article
- A Novel Protein NAB1-356 Encoded by circRNA circNAB1 Mitigates Atrial Fibrillation by Reducing Inflammation and Fibrosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Nanozyme-based visual diagnosis and therapeutics for myocardial infarction: The application and strategy.Journal of advanced research · 2025Review
- Functions and application of circRNAs in vascular aging and aging-related vascular diseases.Journal of nanobiotechnology · 2025Review
- Emerging Circulating Biomarkers for Enhanced Cardiovascular Risk Prediction.Journal of lipid and atherosclerosis · 2024Review
- Machine learning for catalysing the integration of noncoding RNA in research and clinical practice.EBioMedicine · 2024Review
- CircDiaph3 aggravates H/R-induced cardiomyocyte apoptosis and inflammation through miR-338-3p/SRSF1 axis.Journal of bioenergetics and biomembranes · 2024Article
- Long non-coding RNAs in cardiac hypertrophy and heart failure: functions, mechanisms and clinical prospects.Nature reviews. Cardiology · 2024Review
- The Circulating Biomarkers League: Combining miRNAs with Cell-Free DNAs and Proteins.International journal of molecular sciences · 2024Review
- Posttranscriptional Regulation by Proteins and Noncoding RNAs.Advances in experimental medicine and biology · 2024Article
- Research Advances in Targeted Therapy for Heart Failure.Reviews in cardiovascular medicine · 2023Review
- Unlocking the potential of microRNAs: machine learning identifies key biomarkers for myocardial infarction diagnosis.Cardiovascular diabetology · 2023Article
- Cardiac Biomarkers and Their Role in Identifying Increased Risk of Cardiovascular Complications in COVID-19 Patients.Diagnostics (Basel, Switzerland) · 2023Review
15 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
15 authors at 6 institutions in 2 countries.
Funding
Abstract
rationaleNoncoding RNAs (ncRNAs), including microRNAs (miRNAs), circular RNAs (circRNAs), and long noncoding RNAs (lncRNAs), are proposed novel biomarkers of myocardial injury. Their release kinetics have not been explored without confounding by heparin nor has their relationship to myocardial protein biomarkers.
objectiveTo compare ncRNA types in heparinase-treated samples with established and emerging protein biomarkers for myocardial injury. METHODS AND
resultsScreening of 158 circRNAs and 21 lncRNAs in human cardiac tissue identified 12 circRNAs and 11 lncRNAs as potential biomarkers with cardiac origin. Eleven miRNAs were included. At low spike-in concentrations of myocardial tissue, significantly higher regression coefficients were observed across ncRNA types compared with cardiac troponins and cMyBP-C (cardiac myosin-binding protein C). Heparinase treatment of serial plasma and serum samples of patients undergoing transcoronary ablation of septal hypertrophy removed spurious correlations between miRNAs in non-heparinase-treated samples. After transcoronary ablation of septal hypertrophy, muscle-enriched miRNAs (miR-1 and miR-133a) showed a steeper and earlier increase than cardiac-enriched miRNAs (miR-499 and miR-208b). Putative cardiac lncRNAs, including LIPCAR (long intergenic noncoding RNA predicting cardiac remodeling and survival), did not rise, refuting a predominant cardiac origin. Cardiac circRNAs remained largely undetectable. In a validation cohort of acute myocardial infarction, receiver operating characteristic curve analysis revealed noninferiority of cardiac-enriched miRNAs, but miRNAs failed to identify cases presenting with low troponin values. cMyBP-C was validated as a biomarker with highly sensitive properties, and the combination of muscle-enriched miRNAs with high-sensitive cardiac troponin T and cMyBP-C returned the highest area under the curve values.
conclusionsIn a comparative assessment of ncRNAs and protein biomarkers for myocardial injury, cMyBP-C showed properties as the most sensitive cardiac biomarker while miRNAs emerged as promising candidates to integrate ncRNAs with protein biomarkers. Sensitivity of current miRNA detection is inferior to cardiac proteins but a multibiomarker combination of muscle-enriched miRNAs with cMyBP-C and cardiac troponins could open a new path of integrating complementary characteristics of different biomarker types.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.